


cofounder/ceo @wafer_ai. math @uchicago



great read by @packyM, most of the value of technological progress is captured by the consumer: > As Yale economist William Nordhaus found in Schumpeterian Profits in the American Economy, “only a miniscule fraction of the social returns from technological advances over the 1948-2001 period was captured by producers, indicating that most of the benefits of technological change are passed on to consumers rather than captured by producers.” He calculated that producers captured only about 2.2% of the total social surplus from innovation, while consumers captured roughly 97–98%. That 97-98% shows up as lower prices, better products, and higher real incomes for consumers rather than as excess profits.

Congrats to @MarathonMP portfolio companies @niuralHQ and @wafer_ai on being named to The Information's Top 50 Promising Startups! Watching @namibaral @Nabin_Niural @gpuemi and @gpusteve build has been one of my favorite parts of the last year.
Introducing The Information's 50 Most Promising Startups of 2026. The Information selected 50 companies that have the potential to be the most valuable businesses in their categories based on their revenue, business model and growth prospects. To build the list, our reporters consulted industry sources and gathered previously undisclosed financial information. Full list: thein.fo/4AuTSEO

They did it! SpaceX has just caught their Starship rocket for the first time ever, marking the first recovery of a conventional orbital rocket upper stage in history! This is one of the greatest engineering achievements in history. Congrats to the entire @SpaceX team! 🚀

We're selling a $1 for 20 cents. My recommendation: Combine DeepSeek from Token Pass with a frontier subscription and let the agent swarms cook
Vercel Token Pass now offers $150 in tokens for $30 per month. • Use across the 5 models supported today • Available in fx with no extra setup vercel.com/changelog/vercel-…

Vercel Token Pass now offers $150 in tokens for $30 per month. • Use across the 5 models supported today • Available in fx with no extra setup vercel.com/changelog/vercel-…

excited to keep optimizing and giving folks more and more usage! Now $30 dollars for $150 of spend on the top open coding models
Vercel Token Pass now offers $150 in tokens for $30 per month. • Use across the 5 models supported today • Available in fx with no extra setup vercel.com/changelog/vercel-…


Dark, dark day. Horrible decision for the U.S. and the western world.

Microscopy lets scientists literally see the biological world. We think giving agents the same ability will be an important source of progress in science. Today we introduce TissueMicroscopyBench, our first release in a new microscopy series covering tissues, cells, and in vitro systems. The benchmark comprises 49 evaluations built from four public imaging datasets. Agents must locate structures, trace their boundaries, reason through three-dimensional images, and follow changes over time. Some of the work: - Colorectal cancer sections stained with H&E and multiplexed immunofluorescence. Tasks include outlining mucosa, fat, and nerves, and locating evidence of tumor invasion. - Liver metastasis biopsies taken before and after treatment. Agents compare tumor compartments, PD-L1 staining, and T-cell-rich regions across the images. - Light-sheet recordings of living organoids. Overlapping structures and densely packed nuclei require agents to distinguish individual objects and draw their boundaries. - A regenerating leg recorded in three dimensions over time. Tasks examine the injury site, local cell divisions, tissue retraction, and the sequence of regeneration. Compared with our previous benchmarks, these evals are especially visually striking. The rollouts are dense, interleaving image manipulation (including hand-rolled segmentation and CV in Python) with reasoning. Some slides contain billions of pixels. Agents have to decide where to look, examine the relevant regions at sufficient resolution, and return precise outlines, tracks, or volumes. These are scored against expert annotations. Every task was also solved independently by a human as a check on task quality. We tested 22 models in 30 model–harness configurations, with three attempts per task. Claude Fable 5.2 (LSVP) with Pi had the highest pass rate at 34.0%, passing 50 of 147 attempts. Timeouts and invalid answers counted as failures. Twenty-three of the 49 tasks were never solved by any configuration. We found that agents can be shockingly bad at localization, often finding the general region of interest but drawing boundaries that included surrounding tissue or random patches of empty space. Small structures and changes across time were particularly difficult. We think visual perception and spatial reasoning will become core capabilities for scientific agents. It’s also just a super fun space to think creatively about evals (h/t Ian Diks). Excited to release more in this series and watch agents improve here. - Blog: blog.latch.bio/p/tissue-micr… - GitHub: github.com/latchbio/tissuemi… - Leaderboard: benchmarks.bio/tissuemicrosc…

congrats to @WellspinDesign on their official launch today! super proud to have been one of their earliest design partners :)
Meet the new Wellspin. We partner with founders to spin up brands, websites and products, from the first impression to the everyday experience. Let’s build yours: wellspin.design

We’re expanding our benchmark efforts into basic research. Today we introduce NeuroscienceBench, the first release in a new series, with immunology, aging, and other core fields to follow. The goal is to measure whether AI agents can analyze experimental data and reach reliable conclusions about how biology works. We’re starting with neuroscience, where interpreting neural recordings, microscopy images, and animal behavior requires both analytical skill and scientific judgment. NeuroscienceBench comprises 91 evaluations drawn from 43 peer-reviewed studies, spanning sequencing, electrophysiology, EEG, brain–computer interface decoding, imaging, behavior, and clinical biomarkers. Agents analyze experimental data and return structured answers that are graded deterministically. Three public examples: - Neural recordings from the intertrigeminal nucleus. The analysis compares a narrow- and broad-spiking classification derived from the region’s own recordings with the conventional 0.40 ms spike-duration cutoff. - Digital tracings of Lamp5 Lsp1 interneurons from mouse visual cortex. Their cell bodies sit at different cortical depths, and different fractions of their axons reach the outermost cortical layer. The analysis examines whether depth alone accounts for that variation. - A mouse reaching through a narrow slot toward a food pellet. The video contains a pellet and a reflective paw marker with known dimensions, providing possible references for measuring movement in millimeters. We tested 21 models in 34 model–harness configurations, with three attempts per evaluation and no internet access. After excluding platform failures and refusals, 9,212 graded attempts remained. Claude Opus 5.5 with Pi had the highest observed pass rate at 32.2%. The mean across configurations was 21.0%. Across models, evaluations involving quality control, controls, or artifacts averaged a 10.6% pass rate. Those involving normalization or representation choices averaged 12.6%. Reliable neuroscience agents will need to make these decisions correctly across the many types of data scientists work with. Paper: latch.bio/neurobench Leaderboard: benchmarks.bio/neuroscience Blog: blog.latch.bio/p/neuroscienc… GitHub: github.com/latchbio/neuroben… Incredible work from @Jack_Brougher, Anshika Agrawal, @tpr720, Martin Jacko, and team.

Rare diseases collectively affect an estimated 300 million people worldwide. For patients and families, reaching a diagnosis can take years of referrals and testing. One place AI agents could help is in interpreting each new sequencing result or functional assay alongside the patient’s symptoms, family history, and earlier findings. We introduce RareDiseaseBench, a benchmark of 35 diagnostic workups reconstructed from published rare disease cases. Each agent starts with the patient’s presentation and part of the medical record. Over one or more visits, it must decide which tests to request, explain why, analyze the files it receives, and propose a diagnosis and management plan. Five cases from the benchmark: - A 13-year-old boy has growth restriction, hearing loss, and severe chilblains. An MN1 variant explains several developmental findings. Long-read sequencing reveals a translocation disrupting SAMHD1 that accounts for his inflammatory symptoms. - A 21-year-old man has heterotaxy with right atrial isomerism. A variant just beyond the standard ZIC3 transcript falls within an intron of an alternative transcript, causing 57 extra bases to be spliced into the RNA. - A boy develops progressive scalp hair loss while his eyebrows and body hair are preserved. A scalp biopsy shows miniaturized follicles, and sequencing reveals a 357-kb duplication spanning TAB3 and neighboring genes. - A 16-year-old boy with typical growth has a language disorder, learning disability, and autism. He carries two inherited variants in RNU2-2, a small nuclear RNA gene outside the coverage of his exome sequencing. - A boy with delayed motor milestones and enlarged calves has a creatine kinase level of 10,100 U/L. At a second visit, an outside lab reports a DMD inversion. Targeted long reads show duplicated segments containing exons 1 and 2 joined head to head. Each configuration made three attempts on each of the 35 cases. Gemini 4 Argon with Pi passed 46 of 105 attempts (43.8%). Claude Opus 5.5 with Claude Code and GPT-6 Astra with Pi each passed 35 of 105 (33.3%). A pass required the diagnosis and management plan to meet every criterion in the case-specific rubric. Timeouts counted as failures. Among the 14 models that passed at least one case, 2,097 runs failed. Data acquisition and diagnostic workup was the most frequent primary failure category (36%). In 15% of all analyzed failures, the agent failed to pursue the type of data the case required. In another 12%, it omitted a necessary non-sequencing investigation, such as a tissue stain, imaging study, or laboratory test. Paper: latch.bio/raredisease Leaderboard: benchmarks.bio/raredisease Blog: blog.latch.bio/p/raredisease… We think rare disease diagnosis is one of the areas where AI systems have the most potential to make rapid progress and directly benefit patients over the next few years. Incredible work from @chriswzou and team.

Excited to bring Kimi K3.1 Pro to @youdotcom Inference Router at Day-0! Together, we're making Moonshot AI's latest open-weight model production-ready for enterprise teams, backed by a 99.9% uptime SLA from the you.com team. Try it today (link in thread)
Kimi K3.1 Pro is live on Inference Router from day 0. K3.1 is @Kimi_Moonshot's most capable open-weight model yet, with a 1M context window and a reported 65.7% on Terminal-Bench 4.0. Run it in production with at least 99.9% uptime SLA, US hosting and ZDR available. No upfront commitment.

excited to partner with @youdotcom to serve kimi k3.1 pro on inference router from day 0 moonshot ai's latest open-weight model is now available with a 99.9% uptime sla from the you.com team and zero data retention. try it today (link in thread)
Kimi K3.1 Pro is live on Inference Router from day 0. K3.1 is @Kimi_Moonshot's most capable open-weight model yet, with a 1M context window and a reported 65.7% on Terminal-Bench 4.0. Run it in production with at least 99.9% uptime SLA, US hosting and ZDR available. No upfront commitment.